Hello everyone, now that I am 18, I have opened my own brokerage account. Before that I had all my investments through my mother. There I had the $VWRL (+0,06%)
$NOVO B (+1,57%)
$NVDA (-0,03%) ,$ASML (+1,05%) , $Sales
$ADBE (+1,21%) , $ANET (-0,27%) . Due to the share transfer fee, I decided to take advantage of the €1 selling fee and sell everything there. In total, I made a profit of around €200. I have already made a few purchases in my portfolio, but now I have around €4000-4500 free to invest due to the sales, which could also be a good time to make better purchases than at that time. I would therefore like to get some suggestions from you. I would like to have one ETF in my portfolio, which I will save around €250 per month. The rest is open, please give me specific suggestions as to which stocks you consider to be top buys at the moment and also with a specific investment amount of my available money. Please find attached my portfolio and the positions I already have.

Perhaps a few shares will profit from this $NOVO B (+1,57%)
$LLY (+3,13%)

$NOVO B (+1,57%)
$NVO (+2,06%)
$LLY (+3,13%)
$CVS (+1,25%)

https://www.investing.com/news/stock-market-news/eli-lilly-drops-cvs-as-employee-drug-plan-after-weightloss-drug-snub--report-93CH-4349906

Eli Lilly $LLY (+3,13%) is ending its collaboration with CVS Health after CVS discontinued coverage of its weight-loss drug Zepbound in favor of Novo Nordisk's Wegovy $NOVO B (+1,57%) in favor of Novo Nordisk's Wegovy, Bloomberg reports. As of January 1, Lilly employees will transfer to Rightway, a new pharmacy benefits provider.

According to documents seen by Bloomberg, employees covered by Lilly's health plan will be automatically enrolled in drug coverage through pharmacy benefits provider Rightway starting Jan. 1.

The decision came after CVS decided to drop Lilly's weight-loss drug from its benefits package, while continuing to cover the competing product from Novo Nordisk.

... Qualcomm has almost reacted to the level before the breakout...

I bought Novo last week 😅 let's see... in any case, I like the breakout also with regard to a possible end of the fall

07.11.

$NOVO B (+1,57%)
$NVO (+2,06%)
$BMY (+1,1%)

DUBLIN - $NOVO B (+1,57%) has initiated a Phase 3 clinical trial for Coramitug, a potential first-in-class antibody that targets ATTR amyloidosis with cardiomyopathy (ATTR-CM) and breaks down amyloid deposits. This was announced in a press release from Prothena Corporation plc (NASDAQ:PRTA) company. Prothena shares, currently trading at $10.53, have shown strong momentum over the last six months, gaining 41.72%, although they are down 23.97% year-to-date.

The Phase 3 CLEOPATTRA study will evaluate the effects of Coramitug versus placebo on cardiovascular endpoints in patients with ATTR-CM. This development step follows the recent presentation of Phase 2 clinical trial results on November 10 at the American Heart Association Scientific Sessions, which were simultaneously published in the AHA journal Circulation.

Coramitug, formerly known as PRX004, was developed to remove the amyloid deposits associated with disease pathology in both hereditary and wild-type ATTR amyloidosis. The antibody is designed to improve organ function by degrading deposited amyloid and preventing further organ deposition by reducing circulating non-native TTR.

$NOVO B (+1,57%) acquired the worldwide rights to Prothena's ATTR amyloidosis business and pipeline in July 2021. Under the terms of the agreement, Prothena may receive payments of up to $1.2 billion upon achievement of clinical development and sales milestones, of which $100 million has been realized to date. The company will receive an additional clinical milestone payment if pre-specified inclusion criteria are met in the CLEOPATTRA trial.

ATTR amyloidosis with cardiomyopathy is a disease in which abnormal protein deposits accumulate in the heart and impair its function. Current treatments for ATTR-CM aim to stabilize or reduce the production of the native TTR tetramer, while Coramitug's degradative mechanism of action represents a potentially complementary approach.

The information comes from a press release issued by Prothena Corporation.

In other recent news, there has been a lot of movement in the price targets for Prothena shares, with several analyst firms making significant adjustments. H.C. Wainwright raised its price target for Prothena from $20 to $30 and maintained its "Buy" rating. The reason given was that the market was overlooking the company's partner pipeline, which includes promising projects in Phase 3 and Phase 2. Piper Sandler also raised its price target from $15 to $36, emphasizing the potential for significant net sales royalties and milestone payments from Prothena's pipeline. Citizens JMP, however, took a different tack, lowering its price target from $29 to $11, citing concerns following the results of the Phase 1 PRX012 trial in Alzheimer's patients.

Here's something that might interest you: - https://de.investing.com/news/company-news/novo-nordis-startet-phase3studie-zur-behandlung-von-attramyloidose-93CH-3229358

I am currently considering increasing my small $NOVO B (+1,57%) position, as I still believe in the company despite the large drop in the share price (otherwise I would not have bought the shares).

My plan is to buy 5 more shares at a price of €35. I know that's not much, but I'm still 17 years old at the moment, so I can't just buy 100 shares. That would bring my average buy-in to €55, which I think is realistic in a year's time.

What do you think? Should I buy more sooner or later, or maybe not at all? Do you think Novo Nordisk is still on the decline or will the turnaround come soon?

Many thanks in advance!

$HIMS (-1,69%)
Hims & Hers announces the following in its latest quarterly figures:

Talks with Novo Nordisk $NOVO B (+1,57%)
$NVO (+2,06%):

"Hims & Hers and Novo Nordisk are in active discussions to make Wegovy injections and Novo Nordisk's oral Wegovy (if approved by the FDA)
available through the Hims & Hers platform, thereby expanding options for consumers and [doing so] as recommended by the prescribing physician. Hims & Hers notes that discussions are ongoing, no definitive agreement has been signed with Novo Nordisk, and there is a possibility that a definitive agreement with Novo Nordisk may never be signed. In addition, if a definitive agreement is signed, these terms may differ from what is currently expected. Although Hims & Hers may voluntarily disclose the terms of a definitive agreement if and when it is signed, depending on the contours of such an agreement, Hims & Hers may not have a legal obligation to do so."

What happened on 23.06.2025:

Partnership between Novo Nordisk and Hims & Hers collapsed:

-The $HIMS (-1,69%) The share loses over -30% in one day.

Novo Nordisk, the manufacturer of Wegovy, abruptly ended its collaboration with the telemedicine platform Hims & Hers (Hims), which only began in April, on Monday (June 23, 2025).

The two companies are making serious accusations against each other:

1. accusations by Novo Nordisk (manufacturer):

• Illegal copying: Novo accuses Hims of continuing to sell "compounded" (individually mixed) versions of semaglutide (the active ingredient in Wegovy).
• No more bottleneck: According to Novo, the sale of these copies was only allowed during the official drug shortage by the US FDA. However, this bottleneck has been officially declared over.
• Deceptive marketing: Novo accuses Hims of selling these copies en masse under the "false guise of personalization" and engaging in "deceptive marketing."
• Other partners are cooperative: Novo emphasized that partnerships with Hims competitors (such as LifeMD and Ro) remain in place because they have made efforts to switch patients to the original Wegovy.

2. allegations by Hims & Hers (platform):

• Attempted control: Hims CEO Andrew Dudum accuses Novo of trying to "strong-arm" the company.
• Patient control: Novo allegedly tried to control clinical standards at Hims in order to "steer" patients specifically to the more expensive original Wegovy.
• Anti-competitive: Hims describes these claims as "anti-competitive" and an interference with doctors' and patients' freedom of choice.
• Hims continues: Hims announced that it will continue to sell both the original Wegovy and other treatments (including the cheaper, fortified doses).

Source: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ends-collaboration-with-hims-hers-over-weight-loss-drug-sale-2025-06-23/

Due to the tense situation at Novo Nordisk, the company appears to be relenting and entering into renewed talks with Hims & Hers. Apparently there is a change of course by the new CEO and Novo Nordisk recognizes the importance of the Hims & Hers distribution channel. The previous fears of a lawsuit against Hims & Hers have also not materialized.

Coupled with the current good quarterly figures for Q3 2025, this could have a positive impact on $HIMS (-1,69%) have. 🚀